Tracking of Hong Kong stocks concepts | Intensive collaboration + Entry of industry giants, AI pharmaceutical commercialization enters fast lane (with concept stocks)

AI pharmaceutical commercialization accelerates. INSILICO recently announced that its first candidate drug driven by its proprietary generative AI platform has initiated Phase III clinical trials. In early July, the star artificial intelligence (AI) company Anthropic launched the exclusive AI product Claude Science for scientists and pharmaceutical companies, and announced the initiation of an independent drug development project, making a significant impact in the field of AI pharmaceuticals. According to China Securities Co., Ltd., AI has penetrated core processes such as target identification, virtual screening, novel molecular design, ADMET (drug molecular properties) prediction, and automated synthesis, effectively breaking through the throughput limits of traditional high-throughput physical blind screening, significantly improving pharmaceutical efficiency and success rate. In recent years, the AI pharmaceutical market has been heating up. According to incomplete industry statistics, as of the first half of 2026, more than 170 drug pipelines designed or optimized by AI have entered clinical stages globally, with more than ten candidate drugs advancing to Phase III clinical stages. The market outlook is promising as well. According to the "2026-2030 China AI Pharmaceutical Industry Panoramic Research and Strategic Investment Planning Report" published by the China Research PwC Industry Research Institute, the global AI pharmaceutical market is expected to reach approximately $24.9 billion in 2025 and is expected to exceed $46 billion by 2035, with a compound annual growth rate exceeding 33%. The growth rate in the Chinese market is synchronous with the global market, making it one of the most certain incremental markets. In the first half of 2026, INSILICO saw intensive commercial cooperation implementation. The company has successively reached strategic partnerships with Shiseido (with a potential transaction value of $888 million), Lilly ($2.75 billion), SK Biopharmaceuticals ($2.5 billion), and Takeda ($600 million), with a total potential value of nearly $7 billion. In addition to the strategic cooperation with Qilu Pharmaceutical, with a total value of HK$931 million, and the latest cooperation with CMS, its collaboration map is continuing to expand. Traditional pharmaceutical companies are also embracing AI at an accelerated pace. In January 2026, CSPC PHARMA signed a strategic research and development cooperation and licensing agreement with AstraZeneca to develop innovative long-acting peptide drugs using CSPC PHARMA's proprietary sustained-release drug delivery technology platform and peptide drug AI discovery platform. In less than two years, the two parties have reached four early-stage drug development collaborations. In early July, CSPC PHARMA once again reached a strategic agreement with AstraZeneca for a maximum of $1.77 billion, to develop new small nucleic acid candidate drugs using its proprietary siRNA drug discovery platform and liver-targeted delivery platform. In addition, internet giants such as Google, Amazon, and ByteDance are also accelerating their investments in AI pharmaceuticals. On June 10, news of ByteDance's AI pharmaceutical business starting to split and independently raise funds has attracted widespread attention in both the technology and pharmaceutical industries. According to publicly available information, the new company will be led by ByteDance's AI pharmaceutical team, with ByteDance retaining control of the new company. The core team, algorithms, technology platform, and existing pipeline assets of AI pharmaceuticals will enter the new entity as a whole. At the same time, the business will continue to receive computational support from the Volcano Engine. This structure not only retains access to resources from major companies but also further pushes the internal incubated AI for Science (AI4S) business onto a path of independent capitalization. In April of this year, Amazon introduced an AI intelligence body designed for the life sciences, focusing on early drug discovery and shortening the process from computational screening to laboratory testing to a few weeks. In June, NVIDIA officially launched the BioNeMo AI toolkit for scientific workflows, creating a new platform for life sciences. In the same month, OpenAI released the LifeSciBench benchmark test, specifically evaluating the performance of AI models in the field of drug discovery. In April of this year, Anthropic spent nearly $400 million to acquire the AI biotechnology startup Coefficient Bio and released the product Claude Science at the end of June. Google's incubated AI pharmaceutical company Isomorphic Labs also announced in July that its AI-designed drugs are ready to start their first human trials. Shanghai Securities believes that domestic leading AI pharmaceutical companies are making breakthroughs in innovative drug candidate molecule discovery and development, materials research, etc., strengthening their diversified layout, and accelerating from concept validation to clinical value realization and industrial implementation. It is recommended to pay attention to companies such as Metis TechBio. A report from Goldman Sachs pointed out that AI can shorten drug time to market by approximately 20% to 25%, reduce the research and development process by about 3 years, and potentially reduce overall development costs by about 25% to 30%. MoShong Consulting believes that payment and repurchase are the watershed for commercial verification, and pipeline advancement and transaction realization are important signals for platform assetization capabilities. Related concept stocks: INSILICO (03696): INSILICO announced a strategic cooperation alliance with Bora Pharmaceuticals Limited. The alliance will be built on a wide-ranging, multi-faceted cooperation framework. The specific cooperation content will be further discussed and signed into a final agreement by both parties. If fully implemented, the potential total value of this cooperation is expected to exceed $2.5 billion. The proposed cooperation under this alliance will be agreed upon by INSILICO and Bora through subsequent negotiations and signing of a final agreement. It aims to integrate INSILICO's proprietary Pharma.AI platform's technical advantages in target discovery, generative chemistry, and molecular optimization, as well as Bora's professional capabilities in global drug development, manufacturing, quality management, and commercialization. By integrating the AI-enabled research system and automating the development, manufacturing, and quality execution processes, INSILICO and Bora aim to jointly create a new generation of drug innovation model, involving the design and development of novel molecules, manufacturing, and the delivery of drugs to meet the needs of underserved patients. METIS TECHBIO-P (07666): Metis TechBio's core competitiveness lies in the world's first AI nanodelivery platform NanoForge developed independently. Leveraging NanoForge, the company has built over 10 pipeline products. Among them, three leading clinical stage assets, MTS-004, MTS-201, and MTS-105, target disease areas with significant unmet clinical needs and strong commercial prospects. Metis TechBio owns the first AI-empowered new drug MTS-004 completed Phase III clinical trials in China. MTS-004 is China's first and only PBA (pseudo-bulbar affect) drug that has completed clinical trials, filling the gap in domestic PBA drug treatments. XTALPI (02228): On the evening of June 9, XTALPI announced that the Board of Directors was pleased to announce a strategic partnership with a well-known international biopharmaceutical company. The two parties will jointly develop an innovative oral small molecule drug with "Best in-Class" potential for a GPCR (G-protein-coupled receptor) target. This agreement is based on a rigorous and successful pilot phase, where XTALPI integrated quantum physics and AI algorithms to achieve groundbreaking hit rates, verifying the platform's ability to handle such complex metabolism targets. According to the agreement, the partner will make an initial payment to XTALPI and bear all early-stage research and development costs. XTALPI will also receive milestone payments for preclinical, clinical, and commercialization, as well as future sales royalties, with a potential total amount exceeding $400 million. This cooperation model, which deeply links near-term research and development revenues with the long-term pipeline asset value, effectively reduces the costs and risks of XTALPI's participation in high-barrier target research and locks in high potential returns for blockbuster drugs. VIVA BIOTECH (01873): Viva Bio's AI technology accumulated and developed over many years is empowering the entire drug discovery platform. The current AI capabilities cover the full workflow of FIC drug discovery, gradually changing the logic paradigm of drug discovery through end-to-end integration capabilities around new targets, novel mechanisms, and new molecular forms to develop unique AI capabilities that push the company's one-stop original drug development services platform from "AI-assisted" to "AI-driven".